All In Biotech

Drug Trial Radar · NCT01923428

The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of AZD1722 for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

Last checked: Nov 19, 2026Latest source record: Apr 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 356 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

356

Actual

Start

Aug 2013

Primary completion

Oct 2014

Study completion Oct 2014

Sponsor

Lead sponsor
ArdelyxIndustry
Sponsor type
Industry
First posted
Aug 15, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase 2, randomized, double blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of three dose levels of AZD1722 in subjects with constipation predominant IBS (IBS-C) as defined by the ROME III criteria and who have active disease as determined during a two-week screening period. Subjects who qualify and are randomized into the study will receive 5, 20, or 50 mg of AZD1722 BID or placebo BID for 12 consecutive weeks. At the end of this treatment period, subjects will be followed for an additional 4 weeks.

Conditions

  • Constipation Predominant Irritable Bowel Syndrome

Interventions

  • AZD1722Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Complete Spontaneous Bowel Movement Responders vs PlaceboTime frame: 12 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Boulder, Colorado

  • Site not named

    Greensboro, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Chattanooga, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.